Engineered Living Systems Based on Gelatin: Design, Manufacturing, and Applications
- PMID: 39910847
- PMCID: PMC12140921
- DOI: 10.1002/adma.202416260
Engineered Living Systems Based on Gelatin: Design, Manufacturing, and Applications
Abstract
Engineered living systems (ELSs) represent purpose-driven assemblies of living components, encompassing cells, biomaterials, and active agents, intricately designed to fulfill diverse biomedical applications. Gelatin and its derivatives have been used extensively in ELSs owing to their mature translational pathways, favorable biological properties, and adjustable physicochemical characteristics. This review explores the intersection of gelatin and its derivatives with fabrication techniques, offering a comprehensive examination of their synergistic potential in creating ELSs for various applications in biomedicine. It offers a deep dive into gelatin, including its structures and production, sources, processing, and properties. Additionally, the review explores various fabrication techniques employing gelatin and its derivatives, including generic fabrication techniques, microfluidics, and various 3D printing methods. Furthermore, it discusses the applications of ELSs based on gelatin in regenerative engineering as well as in cell therapies, bioadhesives, biorobots, and biosensors. Future directions and challenges in gelatin fabrication are also examined, highlighting emerging trends and potential areas for improvements and innovations. In summary, this comprehensive review underscores the significance of gelatin-based ELSs in advancing biomedical engineering and lays the groundwork for guiding future research and developments within the field.
Keywords: 3D printing; biofabrication; engineered living systems; gelatin; hydrogels.
© 2025 Wiley‐VCH GmbH.
Conflict of interest statement
Conflict of Interest
YSZ consulted for Allevi by 3D Systems, and sits on the scientific advisory board and holds options of Xellar, neither of which however, participated in or biased the work. The relevant interests are managed by the Brigham and Women’s Hospital. The other authors declare no conflict of interest.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL166522/HL/NHLBI NIH HHS/United States
- R21HL168656/Foundation for the National Institutes of Health
- CISE-IIS-2225698/National Science Foundation
- R56 EB034702/EB/NIBIB NIH HHS/United States
- R01HL166522/Foundation for the National Institutes of Health
- UH3TR003274-S1/Foundation for the National Institutes of Health
- R56EB034702/Foundation for the National Institutes of Health
- R01EB028143/Foundation for the National Institutes of Health
- R01CA282451/Foundation for the National Institutes of Health
- UH3 TR003274/TR/NCATS NIH HHS/United States
- R21 EB030257/EB/NIBIB NIH HHS/United States
- R01HL153857/Foundation for the National Institutes of Health
- R01GM134036/Foundation for the National Institutes of Health
- R01 GM134036/GM/NIGMS NIH HHS/United States
- UH3TR003274/Foundation for the National Institutes of Health
- R21 HL168656/HL/NHLBI NIH HHS/United States
- CBET-EBMS-1936105/National Science Foundation
- R21EB030257/Foundation for the National Institutes of Health
- R01 CA282451/CA/NCI NIH HHS/United States
- R01HL165176/Foundation for the National Institutes of Health
- R01 HL153857/HL/NHLBI NIH HHS/United States
- R01 HL165176/HL/NHLBI NIH HHS/United States
- 2022-316712/Chan Zuckerberg Initiative
- R01 EB028143/EB/NIBIB NIH HHS/United States
LinkOut - more resources
Full Text Sources
